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subjects died with progressive leukemia (1 isolated CNS
relapse) and 8/40 died with non-relapse causes.
Conclusions: Efﬁcacy data are encouraging, but the
post-HCT relapse prophylaxis approach with NIL is
limited by QTc prolongation (16% of all registered pa-
tients), early relapse before prophylaxis can begin, and
by miscellaneous post-HCT events that preclude NIL
administration.390
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Introduction: Daily blood cultures during febrile illness are
standard of care in many centers for post allogeneic he-
matopoietic cell transplant patients (alloHCT). The clinical
signiﬁcance of obtaining daily blood cultures for febrile
illness has not been examined to our knowledge in the
literature. Daily blood cultures are associated with iatro-
genic blood loss and central line access. We report the
incidence rate of bloodstream bacterial infections (BBSI)
after four consecutive negative blood cultures between
2000-2013. Other testing modalities for occult infection
including CT scan, viral PCR, and fungal cultures were also
examined.
Methods: A retrospective chart review between 2000-
2013 was conducted. Included were alloHCT patients
with febrile illness (deﬁned as greater than four negative
consecutive blood cultures). The descriptive statistics was
calculated and Fisher’s exact test was used for compar-
ison among rates.
Results: Between 2000-2013, 158 cases in 83 patients
were identiﬁed who met our criteria (mean age 10.6
years). Indication for alloHCT: malignant 62 (74.7%), non-
malignant 21 (25.3%); conditioning regimen:
myeloablative¼ 52 (62.7%) reduced toxicity¼ 10 (12.1%),
reduced intensity¼ 21 (25.3%). Incidence of neutrophil
engraftment by day +30 was 67.5%, and incidence of
aGVHD was 54.2%.
Of those patients with febrile illness, 12% had BBSIs after 4
consecutive negative cultures. Mean time to developing BBSI
was 10.6 (+/- 4.19) days. The most common BBSI was gram
positive cocci (GPC) [89%]. Of these infections, 28% grew
Staphylococcus epidermidis. Gram negative rods (GNR) only
compromised 11% of BBSIs found. A signiﬁcant risk factor for
BBSI was length of febrile illness greater than 7 days
(p¼0.016).
The most obtained modality for identifying other sources
of infection were CT scans and viral studies (both culture
and PCR) [61.2% and 61.4%, respectively]. The rate of positive
results for these tests was 29.1% and 10.9%, respectively.
Other tests utilized to ﬁnd occult infection included fungal
cultures (36.1%) and bronchoalveolar lavage (BAL) (15.3%).
The rate of positivity for these tests was 0.63% and 4.4%
respectively.Discussion: Twelve percent of patients developed BBSI
after 4 sequential days of negative blood cultures, the
majority occurring >7 days of febrile illness. Of those in-
fections, the majority were GPCs possible secondary to
indwelling catheters colonization. Probability of ﬁnding a
true BBSI after 4 negative blood cultures is very low. Of
the different modalities used to search for occult infection,
CT scans have the highest yield in comparison to viral,
fungal or BAL studies, suggesting that obtaining CT scans
earlier in fever may be beneﬁcial. Utility of obtaining daily
blood cultures in febrile alloHCT patients should be pro-
spectively studied.391
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Introduction: ABO incompatibility (ABO-I) in allogeneic
stem cell transplantation is known to produce hemolytic
complications including acute hemolysis, the passenger
lymphocyte syndrome, delayed transfusion dependence and
pure red cell aplasia. Hemolysis is a consequence of ABO
expression on red blood cells (RBCs) and the natural occur-
rence of isohemagglutinins. However, ABO antigens are also
expressed on tissues other than RBCs such as endothelial
cells. It is plausible that donor vs recipient (Minor) ABO-I
may adversely impact organ function and survival after
transplantation. Indeed, in contrast to historic data, one
report found that ABO-I increased non-relapse mortality
(NRM) in reduced intensity transplantation (Resnick et al.,
BBMT 2008). We conducted a large retrospective study to
evaluate the hypothesis that Minor ABO-I impacts overall
survival (OS) and NRM in allogeneic stem cell
transplantation.
Patients and Methods: We analyzed 374 patients who had
undergone allogeneic transplants for hematologic malig-
nancies from HLA-matched sibling donors between the
years 1993e2014. 71 patients had either Minor (including
bidirectional) ABO-I, 55 patients had Major (recipient vs
donor) ABO-I, and 248 patients had no ABO-I. The median
age at transplantation was 38 years. 162 (43%) had AML/
MDS, 120 (32%) had CML/CMMoL, 63 (17%) had ALL, 18 (5%)
had NHL/CLL and 14 (4%) had other diagnoses. 344 (92%)
received a Cytoxan/TBI-based myeloablative conditioning
and 30 (8%) received reduced intensity conditioning. The
graft source was either peripheral blood stem cells in 336
(90%) or bone marrow in 38 (10%) and was ex vivo T cell
depleted in 99%. There were no signiﬁcant differences be-
tween Minor ABO-I and other groups with respect to
baseline variables. Kaplan-Meier estimates were used to
determine OS, NRM and cumulative incidence of relapse,
with differences between groups determined by the log-
rank test.
Results: At a median follow up duration of 11 years, the OS
for Minor/bi ABO-I was 43% vs 40% for others (p¼0.8). NRM
was 38% for Minor/bi ABO-I vs 42% for others (p¼0.6). The
cumulative incidence of relapse was 58% for Minor/bi ABO-I
vs 50% for others (p¼0.1). Findings were similar when ABO-I
status was categorized into three groups (Major, Minor/bi vs
Figure.
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Conclusion: In this large study of mostly myeloablative, T-
cell deplete, allogeneic transplant patients the presence of
donor vs recipient Minor ABO-I did not signiﬁcantly impact
critical long term outcomes.
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Background: VRE is a common cause of BSI and daptomycin
is often used as ﬁrst-line therapy. The Clinical and Laboratory
Standards Institute (CLSI) deﬁnes VRE isolates with dapto-
mycin MIC (D-MIC) of 4 mg/L as susceptible. Clinical sig-
niﬁcance and treatment outcomes of VRE BSI episodes with
D-MIC of 4, compared to those with D-MIC of 2 is currently
undeﬁned.
Patients and Methods: A single-center retrospective chart
review of adults with hematologic malignancies and HSCT
(autologous and allogeneic) recipients diagnosed with VRE
BSI between September 2006 and September 2014 was
performed. D-MICs were determined using Etest and VRE
isolates with MICs <2 or >4 were excluded from the study.
Only the ﬁrst VRE BSI episode per patient was included.
Results: 53 BSI episodes were identiﬁed in 59 patients (27
allogeneic and 3 autologous HSCT; 29 with hematologic
malignancies); of which 47.2% (25 of 53) and 52.8% (28 of 53)
were due to isolates with D-MICs of 4 and 2 respectively. The
median duration of bacteremia (4 versus 3 days; p ¼ 0.20),
median duration of neutropenia (15 vs. 17 days; p ¼ 0.78),
and Pitt Bacteremia Score (p ¼ 0.51) did not differ signiﬁ-
cantly between patients with VRE BSI due to D-MICs of 4 and
2. The all-cause 30-day mortality after onset of BSI was 44.4%
(D-MIC: 4) vs. 55.6% (D-MIC: 2) in HSCT recipients and 33.3%
(D-MIC: 4) vs. 55.6% (D-MIC: 2) in patients with hematologic
malignancies. 100% of the episodes were due to Enterococcusfaecium, with central venous catheters identiﬁed as the most
common source of BSI. Daptomycin monotherapy was the
most common treatment choice, used in 80% (47 of 59) of the
BSI episodes.
Conclusion: The all-cause 30-day mortality, duration and
severity of bacteremia did not appear to be different between
VRE BSI episodes with D-MICs of 4 versus 2 in HSCT re-
cipients and patients with hematologic malignancies.
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Introduction: The outcome of allo-SCT in patients with poor
risk leukemia is still hampered by GVHD and relapse. The
innate immune system has been reported to contribute to
tumor control, with lower incidence of GVHD. Speciﬁc
depletion of abT-cells e key players in the development of
GVHD e will render NK cells and gd T cells within the allo-
graft. Recently reported results have shown the great
promise of this approach in haploidentical transplantations.
Within this study, we aim to extend abT-cell depleted allo-
SCT to patients with a MRD or MUD.
Methods: Patients with either ‘poor-risk’ or ‘very poor-risk’
leukemia were included in this phase I study. Either HLA
matched siblings (MRD) or HLA matched (9 or 10/10) unre-
lated donors (MUD) were eligible. abT-cell reduction was
performed by negative selection with anti-abTCR antibodies
in combination with magnetic microbeads, using the auto-
mated CliniMACS device (Miltenyi Biotec, Bergisch Gladbach,
Germany). The maximal contamination with abT-cells for all
dose levels was 5x105/kg. The conditioning regimen con-
sisted of: ATG (Genzyme) 4 or 6 mg/m2 + ﬂudarabine 120
mg/m2 + busilvex AUC¼90 followed by abT-cell depleted
grafts from matched related or unrelated donors. No addi-
tional immune suppression was given after allo-SCT.
Results: Products for 15 patients have been successfully
processed and used for abT-cell depleted allo-SCT between
2013 and 2014. A w4 log depletion of abT-cells has been
observed in the product with a recovery of w75% of CD34+
cells. The combination of ATG/ﬂudarabine/busilvex was well
tolerated with a hematological recovery within 3 weeks.
Primary engraftment (chimerism > 95%) was observed in all
patients. Immune reconstitution primarily consisted of
innate cells (NK cells and gd T cells) the ﬁrst 6 months post
